To assess the effects of intravenous tolazoline on hemodynamics and regional blood flow distribution, 12 anesthetized newborn piglets were studied. Six piglets received saline and served as controls, the other 6 received two bolus doses of tolazoline(1 and 2 mg/kg). Mean arterial blood pressure decreased from control levels of 69.4 ± 5.6 to 54.6 ± 7.0 and 47.0 ± 5.6 mm Hg, respectively, after 1 and 2 mg/kg of tolazoline, and heart rate increased from 220 ± 9 to 270 ± 13 and 282 ± 8 beats/min, respectively. Cardiac output and regional blood flows were measured 15 min after tolazoline by the radioactive microsphere technique. Cardiac index did not change significantly. There was a redistribution of cardiac output toward the coronary circulation, with an increase in coronary blood flow from a control value of 249.3 ± 39.9to 361.0 ± 56.4 ml/min/100 g of tissue after 1 mg/kg of tolazoline. Bronchial blood flow was also significantly increased. After a dose of 2 but not 1 mg/kg, the renal blood flow was markedly decreased from 139.8± 17.8 to 104.4 ± 24.5 ml/min/100g. The other regional blood flows were not significantly modified. We conclude that tolazoline is a potent coronary vasodilator during the neonatal period. In addition we speculate that the decrease in renal blood flow might play a role in the renal toxicity of tolazoline.

Keywords:
Tolazoline, Newborn piglet, Regional blood flow, Radioactive microspheres
This content is only available via PDF.
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.